Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor

Summary

TERAVECT is a phase III randomized study of patients with digestive neuroendocrine tumors after complete surgical resection of liver metastases treated with In111-Pentetreotide-based adjuvant radiotherapy. In this study, targeted radionuclide therapy is used at an earlier stage of the disease.The objective is to target residual tumor cells and/or micrometastases which escaped surgical resection. Given the poor prognosis associated with recurrence, this treatment should prevent relapse.

Timeline

Start

2015-09

Primary completion

2018-10-11

Completion

2018-10-11

Outcome

Outcome not reported

Stopped (Enrollment): “Although the relevance of this study remains, the recruitment was too slow (4 patients in 2 years).”

Drugs

Indications